Pramodini Medicare Ltd. Share Price

Pramodini Medicare

• Pramodini Medicare is coming out with an initial public offering (IPO) of 58,51,200 shares in a price band of Rs 110 - 118 per equity share.
• The issue will open for subscription on August 12, 2026 and will close on August 14, 2026.
• The shares will be listed on SME Platform of NSE.
• The face value of the share is Rs 10 and is priced 11.00 times of its face value on the lower side and 11.80 times on the higher side.
• Book running lead manager to the issue is Smart Horizon Capital Advisors.
• Compliance officer for the issue is Rushikesh Vijay Gosavi.

Profile of the company

Pramodini Medicare India is a diagnostic service provider in India. It provides a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India. Its diagnostic services include a comprehensive range of offerings: i) ‘Radiology’ which covers Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), X- ray, Ultrasound with colour doppler, Mammography, Dexa Scan and Intervention Radiology, ii) ‘Clinical Laboratory’ which includes Haematology, Micro-Biology, Immunology, Pathology & Bio-Chemistry and (iii) ‘Nuclear Medicine’ which includes PET-CT (Positron Emission Tomography-Computed Tomography), SPECT (Single Photon Emission Computed Tomography) and Nuclear therapy. It also provides teleradiology services through its registered office situated at Vijayawada which functions on a 24x7 basis throughout the year. It provides healthcare services for core testing, patients diagnosis, disease prevention and monitoring of various health conditions. Its services include both routine and specialized tests, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of diseases.

Its business operates across four key models namely i) Public Private Partnership (with government hospitals and government teaching hospitals) ii) Private Private Partnership (with private sector hospitals) iii) Strategic Partnership with PSUs (Public Sector Undertakings) Government of India and iv) Private Centres (standalone centre). The above models are based on hospital partnerships, where diagnostic centres are set up within the existing premises of hospitals, health centres and it supports them by providing diagnostic testing service. It has entered into Memorandum of Understandings (MOUs) with these institutions for the establishment and operation of onsite diagnostic centres within their existing healthcare facilities. It is operating through 16 diagnostic centres across these different models. These centres are located in 7 states in India: Uttar Pradesh, Andhra Pradesh, Karnataka, West Bengal, Haryana/NCR Delhi, Madhya Pradesh and Kerala (Operation yet to commence). The services offered at each location vary based on the scope agreed under the respective MOUs. It has presence across 14 cities in India. It also has a processing unit cum laboratory in Vijayawada.

It offers a one-stop solution for all services to its patients through its operational network. It also offers customized health and wellness packages tailored to meet the specific requirements of its patients. It focuses on a patient centric approach to enhance the overall quality of its services for optimal patient’s satisfaction. Several factors, including integrated services model, quality of its diagnostic services, centre infrastructure and patient’s experience, convenience of its operational network in its core geographies are important differentiating factors in patients choosing it as their preferred and trusted diagnostic service provider, which helps it in retaining its patients, and sets it apart from its competitors.

Proceed is being used for:

• Funding of capital expenditure for purchase of medical equipments towards Existing and proposed diagnostic centres
• General corporate purposes and unidentified inorganic acquisition

Industry overview

Healthcare has become one of India's largest sectors, both in terms of revenue and employment. The industry is growing at a tremendous pace owing to its strengthening coverage, service and increasing expenditure by public as well private players. The global remote patient monitoring market is projected to expand at a CAGR of 12.7% to reach $56.94 billion by 2030. India’s hospital market is expected to be valued at $135.3 billion in FY2026 and is projected to reach $202.5 billion by 2030, growing at a CAGR of around 10.6%. Meanwhile, India held the 41st position in IMD’s World Competitiveness Index 2025 and 38th position in the Global Innovation Index, highlighting growing capabilities in healthcare innovation, digital health, and research ecosystems.

Rising income levels and an expanding middle class are driving higher healthcare spending and demand for quality services across India. Greater penetration of health insurance aided the rise in healthcare spending, a trend likely to intensify in the coming decade. Growing insurance penetration is supporting affordability, with standalone health insurers reporting 10.4% YoY premium growth to Rs 3,622 crore ($422.7 million); total premium income is expected to reach Rs. 3.21-3.24 lakh crore ($37.6-37.9 billion), followed by further growth of around 10.9% in FY27. Economic prosperity is driving the improvement in affordability for generic drugs in the market. The Union Budget 2026-27 marks a significant step in strengthening India’s healthcare system, with allocation to the Ministry of Health & Family Welfare increased to Rs 1,06,530.42 crore ($12.05 billion), reflecting a around 10% rise over the previous year. Continued policy support and investment are enhancing healthcare infrastructure, expanding access, and driving long-term sector growth.

Further, India’s healthcare sector is extremely diversified and is full of opportunities in every segment, which includes providers, payers, and medical technology. India is a land full of opportunities for players in the medical devices industry. The country has also become one of the leading destinations for high-end diagnostic services with tremendous capital investment for advanced diagnostic facilities, thus catering to a greater proportion of the population. Besides, Indian medical service consumers have become more conscious towards their healthcare upkeep. Rising income levels, an ageing population, growing health awareness and a changing attitude towards preventive healthcare are expected to boost healthcare services demand in the future. Greater penetration of health insurance aided the rise in healthcare spending, a trend likely to intensify in the coming decade.

Pros and strengths

Establishing a strategic presence across various states of India: Its network of diagnostic centres spans 7 states across India namely Uttar Pradesh, Andhra Pradesh, Karnataka, West Bengal, Haryana/NCR Delhi, Madhya Pradesh and Kerala (Operation yet to commence). It has 16 centres across 14 cities in India. It commenced operations in Fiscal 2015 with one radiology diagnostic centre. It has 3 centres in Uttar Pradesh, 6 centres in Andhra Pradesh, 3 centres in Karnataka, 1 centre in West Bengal, 1 centre in Haryana/NCR Delhi, 1 centre in Madhya Pradesh and 1 centre in Kerala (Operation yet to commence). It has an operational footprint in each state where it conducts its business, and in connection with its operations, it has set up and manages diagnostic centres within those respective states. The combination of its position driven by its operating history in its core geographies, its operational network and its reputation for providing quality diagnostic services positions it well to continue to grow the scale of its business and take advantage of growing Indian diagnostic market. 

Technical capability with robust IT infrastructure: One of the key contributors to its success in terms of accuracy, turnaround time and scale of operations is the technology infrastructure that it implements as part of its operations. Its technical capability and ability to adopt to the latest technologies in the diagnostic centres allow it to provide quality and reliable diagnostic services to its patients. Its ability to deploy latest equipment and technologies ensure that its processes are efficient and scalable with minimal errors. It has relationships with its equipment vendors which it ensures timely deployment of machinery, advantageous asset pricing, fleet-wide maintenance and preferred vendor status with certain of its equipment suppliers. On account of its scale of operations, it is able to negotiate favorable terms for procurement of equipment from its vendors. In its radiology segment, it deploys MRI, CT scan, X-ray machines, Ultrasound, Dexa Scan and Mammography while its pathology services use fully automatic analysers to run a range of basic to specialized tests. These scanners are capable of performing specialized investigations with minimum radiation dose to the patient and produce quality images to provide accurate diagnosis. Its X-ray systems have computed and digital radiography which are quicker, accurate and produce less radiation to patients than traditional systems. The ultrasound examinations it conducts at various locations are equipped with technology that is capable of 2D and 3D imaging.

Track record of revenue and financial performance: The company has demonstrated a consistent track record of revenue growth and stable financial performance over the years, supported by the expansion of its diagnostic network and an increasing patient base. Its financial performance reflects its ability to effectively scale operations, optimize resource utilization and maintain operational efficiency. It operates 16 diagnostic centres across different operating models, located across 7 states and 14 cities in India. With its continued focus on expanding diagnostic capabilities, strengthening infrastructure and improving service quality, it is well positioned to sustain its growth momentum and further enhance its financial performance.

Risks and concerns

Significant revenue from public private partnership: A significant portion of its revenue from operations is derived from MOUs with government authorities under Public Private Partnership arrangements. For FY 2025-26, 2024-25 and 2023-24, its Public Private Partnership accounted for 54.19%, 70.88% and 77.22% of total revenue from operations, respectively. Any non-renewal, modification, or termination of such MOUs, or delays or failures in realizing payments from government authorities, may materially and adversely affect its business, financial condition and results of operations. 

High revenue concentration in radiology services: Its focus on radiology services has been a characteristic of its service model. It has made investments in imaging modalities such as CT, MRI, PET-CT, and X-ray, positioning itself as a provider of radiology diagnostic solutions. For the FY 2025-26, 2024-25 and 2023-24, its radiology services accounted for 97.05%, 96.17% and 95.82% of total revenue from operations, respectively. However, this emphasis on radiology services also exposes it to risks that could impact its operations, financial performance, and growth prospects.

Dependence on contractually fixed pricing: The prices that it charges for its services are fixed under the MOU it enters with public sector enterprises, state governments and some of private medical establishments. Reference prices of services, pricing limits imposed by them may limit its ability to determine or revise the prices of the services it offers. Other than certain escalation terms, it has limited ability to determine the prices of the services it offers at its diagnostic centres. Further, the escalation clauses included in the MOUs it has entered into may not be in line with inflation linked costs or even the actual increase in expenses incurred in its operations. This could have a material adverse effect on its business, results of operations, financial condition and prospects. Further, if the state governments implement mandatory pricing regimes, its margins could deteriorate which in turn could have a material adverse effect on its business, results of operations, financial condition and prospects.

Outlook

Pramodini Medicare is engaged in offering comprehensive solutions for pathology and radiology testing services such as imaging (including radiology), pathology/clinical laboratory and tele-radiology to customers across states. It provides a range of technology-enabled diagnostic services such as radiology, clinical laboratory, nuclear medicine services to public hospitals, private hospitals, certain PSU of Govt of India and medical colleges across tier I, tier II and III cities throughout India. The services offered at each location vary based on the scope agreed under the respective MOUs. Its business operates across four key models namely i) Public Private Partnership, ii) Private Private Partnership, iii) Strategic Partnership with PSUs (Public Sector Undertakings) Govt of India and iv) Private Centres (standalone centre). On the concern side, it derives substantial portion of its revenue from the state of Andhra Pradesh. For financial year ended March 31, 2026, 2025 and 2024, its revenue from state of Andhra Pradesh is accounted for 61.90%, 84.78% and 86.66% of total revenue from operations respectively. Any loss of business in such regions could have an adverse effect on its business, results of operations and financial condition.

The company is coming out with a maiden IPO of 58,51,200 equity shares of face value of Rs 10 each. The issue has been offered in a price band of Rs 110-118 per equity share. The aggregate size of the offer is around Rs 64.36 crore to Rs 69.04 crore based on lower and upper price band respectively. On performance front, revenue from operations increased by 62.90% from Rs 3,823.77 lakh in Fiscal 2025 to Rs 6,228.75 lakh in Fiscal 2026. Profit after tax increased by 57.58% from Rs 1,102.76 lakh in Fiscal 2025 to Rs 1,737.73 lakh in Fiscal 2026.

Meanwhile, it is strategically focused on strengthening its capabilities and infrastructure by adopting advanced technologies to maintain its position in the diagnostic industry. In order to cater to the growing demand for its services from existing patients and to meet the requirements of new patients, it intends to expand the capacities of certain of its existing diagnostic centres. Accordingly, it proposes to utilize a portion of the Offer Proceeds towards the purchase and installation of medical equipment at some of its existing diagnostic centres located in Hubli (Karnataka), Manjeri (Kerala) and Vijayawada (Andhra Pradesh). Going forward, it intends to augment its growth by pursuing selective acquisitions, joint ventures, strategic alliances and associations that provide it access to technology expertise, specialised services, market share and wider geographical reach, enabling it to expand its service offerings and grow its patient base.

Symbiotec Pharmalab

• Symbiotec Pharmalab is coming out with a 100% book building; initial public offering (IPO) of 1,87,34,736 shares of face value Rs 2 each in a price band Rs 938-988 per equity share. 
• Not more than 50% of the issue will be allocated to Qualified Institutional Buyers (QIBs), including 5% to the mutual funds. Further, not less than 15% of the issue will be available for the non-institutional bidders and the remaining 35% for the retail investors.
• The issue will open for subscription on August 24, 2026 and will close on August 27, 2026.
• The shares will be listed on BSE as well as NSE.
• The face value of the share is Rs 2 and is priced 469 times of its face value on the lower side and 494 times on the higher side.
• Book running lead managers to the issue are JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial Advisory and Securities (India).
• Compliance officer for the issue is Salil Jain. 

Profile of the company

The company is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms- organic chemistry, biotechnology and complex injectables. It has a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs). The company is the only Indian and global company to have a presence across the top 10 corticosteroid and steroidal-hormone APIs demonstrating the depth of its portfolio. It manufactures these products using fermentation and multi-step complex chemical reactions.

With over 30 years of industry experience, it has evolved from a labscale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated platform with approvals from the United States Food and Drug Administration (USFDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea and other global organisations. It has leveraged its deep capabilities across organic chemistry, biotechnology, and complex injectables to operate as a contract development and manufacturing organisation (CDMO) variably for specialty pharmaceutical and nutraceutical companies globally, offering products and services across the three platforms in which it also manufactures its own products.

The company has a robust product portfolio of over 60 corticosteroid and steroidal-hormone APIs that are supplied globally, including Hydrocortisones, Betamethasones, Methylprednisolones, Progesterones, Estrogens and Testosterones, which are used extensively in critical care setups, as well as across chronic therapeutic areas such as respiratory, dermatology, pain management, oncology and gynaecology. Its capabilities span three interlinked platforms: (i) organic chemistry, including flow chemistry, hydrogenation, and photochemistry; (ii) biotechnology, including biosynthesis and biotransformation, and recombinant biologics, including Glucagon-like Peptide-1 (GLP-1) and Insulins; and (iii) forward integration into complex injectables including double-chamber vials, double-chamber bags and double-chamber syringes, collectively enabling it to commercialise and scale hard-to-replicate products and services.

Proceed is being used for: 

• Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company
• General corporate purposes

Industry overview

India has been aptly crowned the Pharmacy of the World, particularly for its manufacturing prowess and contributions to the global pharma sector. India is the largest provider of generic medicines worldwide, holding a 20% share in global supply by volume, encompassing a diverse range of 60,000 generic brands across 60 therapeutic categories. The industry's global reach is underscored by the fact that India exports pharmaceuticals to over 200 countries, supplying more than 50% of Africa's generic medicine needs, almost 40% of the generic demand in the US, and approximately 25% of all medicines in the UK.

India is among the largest global exporters of APIs, supported by efficient processes, regulatory expertise, scale, and cost advantages. API exports grew from $4.2 billion in 2020 to $4.9 billion in 2025, a CAGR of 3.1%, despite increased domestic consumption as local manufacturers supply more to Indian formulation companies. Exports are projected to reach $6.4 billion by 2030, reflecting a 5.5% CAGR from 2025 to 2030. Exports to regulated markets rose from $1.9 billion in 2020 to $2.3 billion in 2025 (3.9% CAGR) and are expected to reach $3.2 billion by 2030. Exports to emerging markets increased from $2.3 billion to $2.6 billion (2.5% CAGR) between 2020 and 2025 and are projected to reach $3.2 billion by 2030 (4.2% CAGR).

India’s deep-rooted credibility in highly regulated markets illuminates its end-to-end manufacturing competence. In Q1 2025, Indian companies accounted for 48% of all USDMF49 submissions. Additionally, in 2025, Indian companies operated more than 220 US FDA-approved API manufacturing facilities, significantly outpacing counterparts in the US and China. Additionally, India had 156 facilities approved for either formulations or formulations plus APIs, demonstrating its manufacturing capabilities50. This regulatory proficiency enables India to meet the global demand for APIs and FDFs seamlessly, offering a reliable, high-quality, and scalable supply base across various therapeutic categories.

Pros and strengths 

Long-standing relationships with domestic and global customer base: As of March 31, 2026, it served over 200 customers across more than 40 countries, supported by its strong focus on quality assurance, scale of operations and ability to ensure consistent supply of complex APIs. its customer portfolio comprises key generic and specialty pharmaceutical companies in global markets such as North America, Europe, and Asia, including several pharmaceutical majors and formulations companies. As of March 31, 2026, it had over 50 domestic customers and over 150 export customers. It has consistently added new customers over the last three Fiscals, contributing to continued expansion of its commercial footprint. In the Fiscals 2026, 2025 and 2024, it added 101, 96, and 89 new distinct customers.

Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record: The company had two operational industrial-scale API manufacturing facilities and had commissioned two additional manufacturing facilities, leading to an aggregate maximum chemical synthesis capacity of 584.67 MT, fermentation capacity of 700 KL, and complex injectables capacity of 20 million vials. In addition, it is in the process of expanding its biologics capacity by adding a dedicated 14 KL (comprising two reactors of 7 KL each) fermentation capacity for biologics manufacturing at its proposed Biologics Facility in Ujjain, to cater to the increasing demand for GLP-1 and Insulin. As of March 31, 2026, it was among the few players in India to possess multi-scale fermenters, enabling it to produce both high-volume and low-volume fermentation-based products. This scale diversity also enables it to offer flexible CDMO services across various production volumes, including support for fermentation-based product development initiatives and complex injectables partners. The company has maintained a track record of regulatory adherence, having successfully completed 11 inspections from regulatory agencies and over 90 customers over the last three Fiscals, 2026. Notably, it has not received any critical observations from global regulators in course of their inspections during the last three Fiscals.

Continuous investment in R&D: Its innovation and an R&D-led development ethos have contributed to the growth of its operations and enabled it to build capabilities in industrial-scale steroidal and hormonal organic chemistry, as well as fermentation technologies across modalities ranging from bioconversion to biosynthesis and precision fermentation. Through continuous investment in R&D, it has evolved from a lab-scale manufacturer undertaking five to six step chemistry into an industrial-scale manufacturer with differentiated chemistry capabilities, enabling it to manufacture APIs and products collectively with up to 400 synthesis steps validated under cGMP efficiently. Its R&D capabilities support the development of complex, science and technology-based product offerings across APIs, fermentation-based products, complex injectables and drug–device combinations.

Robust financials with strong gross margins, high capital efficiency and cash conversion: The company has demonstrated a consistent track record of strong financial and operational performance. Its revenue from operations increased from Rs 7,162.47 million in Fiscal 2024 to Rs 7,515.54 million in Fiscal 2025 and further to Rs 8,691.49 million in Fiscal 2026, representing a CAGR of 10.16% between Fiscals 2024 and 2026, driven by robust global demand for its API products. Its high margin profile has been supported by a combination of improved product mix, increasing supplies to regulated markets, operational efficiencies, and controlled raw material prices. These factors have contributed to a significant improvement in its EBITDA margins, which increased from 24.48% in Fiscal 2024 to 27.26% in Fiscal 2025 and to 26.59% in Fiscal 2026, and it has already made investments into, and committed operational resources towards, its complex injectables and CDMO platform for future growth. Its financial performance and credit ratings reflect its disciplined financial management and prudent capital allocation practices.

Risks and concerns

High revenue concentration in API products: The company derives almost all of its revenue from the sale of APIs, which collectively constituted 96.07%, 99.10% and 100.00% of its revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Further, its top five APIs constituted 62.27%, 63.16% and 60.37% of its revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Any reduction in demand for APIs, and its top products in particular, or disruption in production, could have an adverse effect on its business, results of operations, financial condition and cash flows. Further, if its API production is interrupted due to equipment failure, supply chain disruptions, regulatory noncompliance, or other operational challenges, or if it fails to procure high-quality APIs in the quantities it requires on a cost-effective basis, the sales and distribution of its products could be delayed or interrupted.

Risks associated with export sales and overseas operations: The company exports its products to various countries, and its revenue from external customers outside India represented 67.04%, 55.19% and 59.97% of its revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Its inability to manage the risks associated with its export sales could adversely affect its sales to customers in foreign countries, its results of operations, financial condition and cash flows. Further, as part of its overseas business operations, it may engage with government institutions and agencies in various jurisdictions. Such engagements expose it to risks including complex regulatory requirements, delays in decision-making, changes in government policies, and potential compliance challenges.

Dependence on top ten customers for revenue: The company derives a substantial portion of its revenue from certain key customers, including large pharmaceutical companies to whom it supplies products across multiple therapeutic categories. These customers rely on the company for consistent quality and timely delivery. Revenue generated from its top ten customers accounted for 57.59%, 55.90% and 61.65% of its revenue from sale of product in Fiscals 2026, 2025 and 2024, respectively. Loss of its relationship with any of these customers or delays or reductions in their orders could have an adverse effect on its business, results of operations, financial condition and cash flows. Further, since it does not maintain long-term contractual arrangements with its customers and rely on purchase orders, it is exposed to the risks of customer cancellations, delays, or order reductions, which could adversely affect its results of operations, financial condition and cash flows.

Supplier concentration and raw material supply chain risks: The company relies on securing timely supplies of raw materials for its manufacturing process. The company depends on certain suppliers for raw materials for its operations. Purchases from its top ten suppliers accounted for 25.50%, 18.41% and 50.33% of its total expenses in Fiscals 2026, 2025 and 2024, respectively. Any loss of such suppliers or non-performance of their obligations could adversely affect its business, results of operations, financial condition and cash flows. Its reliance on key suppliers presents several risks, including potential shortages of raw materials, increased costs, and reduced control over delivery schedules. Additionally, some suppliers may not have the capacity to handle sudden increases in orders for raw materials or may prioritise other customers over us. This uncertainty in its supply chain can result in increased costs as it may need to source materials at higher prices.

Outlook

Symbiotec Pharmalab is engaged in the business of manufacturing and selling of Active Pharmaceuticals Ingredientsvand Intermediates. It caters to both domestic and international markets. The company has a robust product portfolio of over 60 corticosteroid and steroidal-hormone APIs that are supplied globally, including Hydrocortisones, Betamethasones, Methylprednisolones, Progesterones, Estrogens and Testosterones, which are used extensively in critical care setups, as well as across chronic therapeutic areas such as respiratory, dermatology, pain management, oncology and gynaecology. On the concern side, the company procures a portion of its raw material requirements from different countries, including China and the United States. Any adverse developments in these countries, or the laws governing its imports from these countries, could disrupt its raw material supply and adversely affect its results of operations, financial condition and cash flows. further, it faces competition both within its API manufacturing business and in its role as a CDMO, which it has recently commenced. An inability to compete effectively may adversely affect its business, results of operations, financial condition and cash flows.

The issue has been offering 1,87,34,736 shares in a price band of Rs 938 -988 per equity share. The aggregate size of the offer is around Rs 1,757.32 crore to Rs 1,850.99 crore based on lower and upper price band respectively. Minimum application is to be made for 15 shares and in multiples thereon, thereafter. On performance front, its total income increased by 15.38% from Rs 7,559.79 million in Fiscal 2025 to Rs 8,722.58 million in Fiscal 2026. Its profit for the year was Rs 1,099.03 million in Fiscal 2026 compared to Rs 967.85 million in Fiscal 2025.

Meanwhile, in line with the R&D-focused ethos that has shaped its evolution, it intends to sustain and expand its innovation driven business model by consistently investing in technologies and strengthening its R&D infrastructure. For existing products, its focus will be on reducing manufacturing costs, and improving process efficiencies. Building on its track record of successfully developing complex molecules, such as conjugated estrogen products, it will continue to leverage its scientific expertise and integrated capabilities to address unmet global market opportunities. Its R&D ethos emphasises collaboration with global specialty pharmaceutical companies, academic institutions, and technology partners. It will also continue to invest in automation, digitalisation, and AI-driven process optimisation across its laboratories and manufacturing facilities to reinforce scalability, cost efficiency, and compliance with global regulatory standards, thereby accelerating its time to market.

Colinz Laboratories has informed that the 40thAGM of the Members of the Company is scheduled to be held on Tuesday the 22nd September, 2026, at 2.30 PM (IST) through Video Conferencing ('VC')/ Other Audio-Visual Means (‘OAVM’), as per the directive(s) of Ministry of Corporate Affairs and Securities and Exchange Board of India. As per section 108 of Companies Act,2013, read with Rule 20 of the Companies (Management and Administration) Rule, 2014 and all applicable provisions of the SEBI (LODR) Regulations, 2015, the Company is pleased to provide to its members the facility to cast their Vote(s) through remote e-voting starting from 19th September, 2026 (9.00 am) to 21st September, 2026 (5.00 pm), the cut-off date for remote e-voting is 15th September, 2026. E voting facility will also be available during AGM, to those members who did not exercise e voting during the above period. Pursuant to Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Section 91 of the Companies Act, 2013, the company has enclosed the details of Book Closure dates and calendar of events related to the 40th AGM of the Company.

The above information is a part of company’s filings submitted to BSE.  

Pursuant to Regulation 30 and other applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), Sai Parenterals has informed that it enclosed copies of the Newspaper Advertisement published in PAS-1 by the Company with details regarding proposed change and variation in the objects of utilization of the Initial Public Offering (‘IPO’) proceeds, in compliance with requirement under the Companies Act, 2013. The advertisements were published today (ie. on 20th August, 2026) in the newspapers: Financial Express (English) and Mana Telangana (Telugu). The newspaper publications are also made available on its website at the following link https://www.saiparenterals.com/.

The above information is a part of company’s filings submitted to BSE.